Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00621322
First received: February 12, 2008
Last updated: September 3, 2009
Last verified: September 2009

February 12, 2008
September 3, 2009
April 2008
April 2009   (final data collection date for primary outcome measure)
  • Haematological and biochemical levels in each group. [ Time Frame: At protocol defined time points ] [ Designated as safety issue: No ]
  • Occurrence, intensity and relationship to vaccination of any solicited local and general symptoms in each group. [ Time Frame: During the 7-day follow-up period following vaccination after each vaccine dose ] [ Designated as safety issue: No ]
  • Occurrence, intensity and relationship to vaccination of any unsolicited symptoms in each group. [ Time Frame: During the 30-day follow-up period following vaccination after each vaccine dose ] [ Designated as safety issue: No ]
  • Occurrence and relationship to vaccination of any serious adverse events in each group. [ Time Frame: During the entire study period ] [ Designated as safety issue: No ]
  • Haematological and biochemical levels (safety and reactogenicity) [ Time Frame: At protocol defined time points ]
  • Occurrence, intensity and relationship to vaccination of any solicited local and general symptoms (safety and reactogenicity) [ Time Frame: During the 7-day follow-up period following vaccination after each vaccine dose ]
  • Occurrence, intensity and relationship to vaccination of any unsolicited symptoms (safety and reactogenicity) [ Time Frame: During the 30-day follow-up period following vaccination after each vaccine dose ]
  • Occurrence and relationship to vaccination of any serious adverse events (safety and reactogenicity) [ Time Frame: During the entire study period ]
Complete list of historical versions of study NCT00621322 on ClinicalTrials.gov Archive Site
  • Analysis of cytokines expression by M72-specific CD4+/CD8+ T cells by means of in vitro flow cytometry [ Time Frame: At protocol defined time points ] [ Designated as safety issue: No ]
  • Antibody titres to M72 as measured by ELISA [ Time Frame: At protocol defined time points ] [ Designated as safety issue: No ]
  • Analysis of cytokines expression by M72-specific CD4+/CD8+ T cells by means of in vitro flow cytometry using ICS(immunogenicity assessment) [ Time Frame: At protocol defined time points ]
  • Antibody titres to M72 as measured by ELISA (immunogenicity assessment) [ Time Frame: At protocol defined time points ]
Not Provided
Not Provided
 
Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults
Dose Range Study Evaluating Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccines (692342) When Administered to Healthy Adults Aged 18 to 45 Years.

This observer blind study will assess the safety and immunogenicity of different formulations of GSK Biologicals' 692342 tuberculosis vaccine in healthy adults aged 18 to 45 years with a positive PPD skin test. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Tuberculosis (TB) Infection
  • Biological: Control vaccine with physiological saline
    Intramuscular injection, 2 doses
  • Biological: GSK Biologicals' Candidate Tuberculosis Vaccines (692342) - different formulations
    Intramuscular injection, 2 doses
  • Biological: Control vaccine with the adjuvant system.
    Intramuscular injection, 2 doses
  • Active Comparator: Group F
    Intervention: Biological: Control vaccine with physiological saline
  • Placebo Comparator: Group C
    Intervention: Biological: Control vaccine with the adjuvant system.
  • Experimental: Group E
    Intervention: Biological: GSK Biologicals' Candidate Tuberculosis Vaccines (692342) - different formulations
  • Experimental: Group D
    Intervention: Biological: GSK Biologicals' Candidate Tuberculosis Vaccines (692342) - different formulations
  • Experimental: Group A
    Intervention: Biological: GSK Biologicals' Candidate Tuberculosis Vaccines (692342) - different formulations
  • Experimental: Group B
    Intervention: Biological: GSK Biologicals' Candidate Tuberculosis Vaccines (692342) - different formulations
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
181
April 2009
April 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
  • A male or female between, and including, 18 and 45 years of age at the time of the first vaccination.
  • Written informed consent obtained from the subject prior to any study procedure.
  • Free of obvious health problems as established by medical history and clinical examination before enrolment into the study.
  • If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.
  • No evidence of pulmonary pathology as confirmed by chest X-ray.
  • No history of extrapulmonary TB.
  • Clinically normal laboratory values for creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), complete blood count (CBC) and urinalysis.
  • Seronegative for human immunodeficiency virus-1 and -2 (HIV-1 and -2) antibodies.
  • Subjects must have a PPD positive skin reactivity 48 to 72 hours after PPD skin test administration.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
  • Any chronic drug therapy to be continued during the study period, with the exception of vitamins and/or dietary supplements, herbal medications, birth control pills, anti-histamines for seasonal allergies and SSRIs.
  • History of previous administration of experimental Mycobacterium tuberculosis vaccines.
  • History of previous exposure to experimental products containing MPL or QS21.
  • Administration of any immunoglobulins, any immunotherapy and/or any blood products within the three months preceding the first dose of study vaccination, or planned administrations during the study period.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
  • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
  • A family history (first generation) of congenital or hereditary immunodeficiency.
  • History of any acute or chronic illness or medication that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.
  • History of any neurological disorders or seizures.
  • History of allergic reactions or anaphylaxis to previous immunisations.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • History of chronic alcohol consumption and/or drug abuse.
  • Major congenital defects.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions.
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Philippines
 
NCT00621322
110345
Not Provided
Study Director, GSK
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP